During my time at ASDRP, I worked on antibody-drug conjugates (ADCs) which are an emerging class of cancer therapeutics that involve three main components: a monoclonal antibody, a selectively-degradable linker, and a cytotoxic payload. ADCs are advantageous compared to traditional therapeutics as they can selectively deliver cytotoxic payloads to cancer cells with minimal effects on healthy cells. I mainly focused on the biochemical aspect of our projects, such as culturing cells or performing cell viability assays. Additionally, I worked on the evaluation of the interference of various reductants on tetrazolium-based in-vitro assays, such as the MTT Assay.
Health and Human Biology